FDA, Weight loss

Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Wegovy: New weight loss drug available in Ireland next month
Clinical trials have found that people who are on the prescription for a year can lose more than 10% of their body weight.
Ozempic, Wegovy Linked To Potential Vision Loss
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to people not taking the drug, researchers reported Feb. 20 in JAMA Ophthalmology.
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...
No more needles? Startups are testing patches to deliver weight-loss drugs and other medications.
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
What to know before considering weight loss jabs, as related deaths rise
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
Medical News Today6d
Novel antibody could help prevent bone, muscle loss due to GLP-1 drugs
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
The next phase of the weight-loss revolution holds promise — and peril
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
The next battle in the weight-loss drug war is focussed on muscle growth
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...